Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Specimen Handling 288Magnetic Resonance Spectroscopy 238pembrolizumab 228Carboplatin 187Cisplatin 153Biopsy 151Cyclophosphamide 144Paclitaxel 133Nivolumab 123Gemcitabine 113Bevacizumab 106Radiotherapy 96Dexamethasone 86Pemetrexed 83fludarabine 78Fluorouracil 76Doxorubicin 76Docetaxel 76atezolizumab 73Radiation 72Leucovorin 70Rituximab 68Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 61Vincristine 56Cetuximab 56Lenalidomide 55Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
brigimadlin × 30 days × Clear all
NCT05512377 2026-05-14

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Boehringer Ingelheim

Phase 2 Terminated
99 enrolled
GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡